Mineralys Therapeutics, Inc. MLYS NASDAQ

Mineralys Therapeutics, Inc. (MLYS) reported total assets of $661.81M and total liabilities of $15.11M for quarter ending 2025-12-31, resulting in total equity of $646.69M.

The company held $656.64M in cash and short-term investments. Total debt stood at $0.00, with net debt of $-172.92M. The Debt-to-Equity (D/E) ratio was 0 (conservative).

Current ratio is 43.76, indicating strong short-term liquidity.

Criteria supported by this page:

• HEALTH (100/100, Pass) — Debt-to-Equity of 0, current ratio of 43.76 — balance sheet is strong
• MOAT (40/100) — Total assets $661.81M and equity $646.69M support the company's competitive scale
• VALUE (94/100) — Debt-to-Equity 0 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 56/100 with 3/7 criteria passed.